Abraxis BioScience Gets SFDA Nod For Metastatic Breast Cancer Drug In China
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Abraxis BioScience received approval from China's State FDA to market its metastatic breast cancer drugAbraxane (paclitaxel albumin-bound particles for injectable suspension) in China, the company announced July 14
You may also be interested in...
Biocon Launches U.S. Breast Cancer Drug Abraxane in India
India's Biocon began marketing Abraxane (paclitaxel) in the country for treating breast cancer. Biocon licensed the drug last year from Abraxis BioSciences of the United States. The drug already is approved in 35 countries, but Biocon seeks to feed a growing need for the drug in India. The licensing agreement also covers more than 10 other countries in Asia where regulatory approval is sought, including Pakistan and Sri Lanka. (Click here for more
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).